Abstract
It is the general consensus of scientists that cancer vaccines will become a
reality. Overall the cancer treatment market continues to grow and this demand
sets the stage for vaccine products.
Several promising vaccines: the propholactic Gardasil has created a pathway
for new vaccine products. M-Vax, Ocon-Vax in late stage development and are
preparing for regulatory review in the United States, Europe, Canada, or other
international regions. Many of the products with potential approval status
over the coming years are already in Phase III development, have orphan drug
status, SPA status, or Fast Track status. This provides a promising future for
many of these products. Additionally, some products in international regions
have been granted compassionate use status which is significant in evaluating
need on a patient-by-patient basis. In this report, Kalorama Information
provides a realistic estimate of the cancer vaccine for the near term for the
following products:
- Melonoma Vaccines
- Lung Cancer Vaccines
- Prostate Cancer Vaccines
- Cervical Cancer Vaccines
- Brain Cancer Vaccines
- Colon/Rectal Cancer Vaccines
- Breast Cancer Vaccines
- Lymphoma Vaccines
- Ovarian Cancer Vaccines
- Leukemia Vaccines
- Bladder Cancer Vaccines
As part of its exhaustive research and analysis, this report provides:
- Forecasts for Future Revenues from Cancer Vaccines
- Cancer Epidemiology
- Reviews of Products in the Pipeline
- Detailed Profiles of 13 Companies Operating in the Cancer Vaccine Market
- Directory of Related Companies
Some of the issues discussed in this report important for anyone operating in this market include:
- Introduction
- Early Detection and Screening
- Monoclonal Antibodies and Therapeutic Vaccines
- Political and Social Pressure
- Insurance and Reimbursement Issues
- Personalized Medicine
- Pharmacogenomics
- Vaccine Strategies
- New Genetic Technique
- Future Growth in Vaccines
As part of its detailed coverage of developments in cancer vaccines..the following companies are profiled in this report:
- Antigenics, Inc.
- Avax Technologies, Inc.
- Biovest International, Inc.
- Cell Genesys, Inc.
- Dendreon Corporation
- Genitope Corporation
- GlaxoSmithKline plc
- Merck & Company, Inc.
- Northwest Biotherapeutics, Inc.
- NovaRx
- Oncothyreon
- Vaccinogen
- Vical, Inc.
| 
View Cart
